Sex-based differences in the effect of digoxin for the treatment of heart failure

Saif S Rathore1, Yongfei Wang, Harlan M Krumholz

  • 1Section of Cardiovascular Medicine, Department of Internal Medicine, Yale-New Haven Hospital, New Haven, Conn, USA.

Insights

Digoxin treatment did not reduce mortality in heart failure patients. However, it increased the risk of death in women, while showing no significant effect in men, indicating a crucial sex-based difference.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • The Digitalis Investigation Group (DIG) trial found digoxin did not decrease overall mortality in heart failure patients with reduced ejection fraction.
  • While heart failure characteristics vary by sex, prior trials did not evaluate sex-specific digoxin effects.

Purpose of the Study:

  • To conduct a post hoc subgroup analysis of the DIG trial to determine if there are sex-based differences in digoxin's effect on mortality.
  • To evaluate the interaction between sex and digoxin therapy on all-cause mortality.

Main Methods:

  • A subgroup analysis of 6800 patients from the DIG trial was performed.
  • Mantel-Haenszel tests and multivariable Cox proportional-hazards models were used to assess the interaction between sex and digoxin therapy.
  • Analyses were adjusted for demographic and clinical variables.

Main Results:

  • Digoxin therapy showed a significant interaction with sex regarding all-cause mortality (P=0.034).
  • Women receiving digoxin had a higher mortality rate (4.2% absolute difference) compared to women receiving placebo.
  • Digoxin had no significant effect on mortality in men compared to placebo.

Conclusions:

  • The effect of digoxin therapy on mortality differs significantly between men and women.
  • Digoxin is associated with an increased risk of death in women with heart failure and reduced ejection fraction.
  • Digoxin did not demonstrate a significant impact on mortality in men within the study population.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...